Skip to main content

Pharma/Regulatory

No Recurrent Cancer Risk With Biologic Treatment of RA

MedPage Today
Sep 24, 2021

Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.

Read Article

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article

Guselkumab Treats Axial Disease in Psoriatic Arthritis

Sep 23, 2021

Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.

Read Article

11 Drugs That Cause Arthritis

Sep 23, 2021

This is the #1 question I get from new consults: “How did I get arthritis?”

But as aching patients ask this question, they are really thinking these joint complaints must be due to something.

Read Article

IL-6 Inhibition in Refractory Systemic Sclerosis

Sep 22, 2021

A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype. 

Read Article

Tocilizumab and Drug Shortage Headaches

Sep 22, 2021

Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.

Read Article
ACR Responds to 2022 Medicare Physician Fee Schedule Proposed Rule Read more: https://t.co/SVGhfhp6Fg #RheumNow #RheumTwitter #medtwitter https://t.co/g46wYCdary
Dr. John Cush @RheumNow( View Tweet )
Sep 17, 2021

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

Sep 16, 2021

Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.

Read Article

ACR Responds to 2022 Medicare Physician Fee Schedule Proposed Rule

ACR
Sep 16, 2021

In comments submitted to the Centers for Medicare and Medicaid Services (CMS), the American College of Rheumatology (ACR) shared its perspective on the CY 2022 Medicare Physician Fee Schedule and Quality Payment Program proposed rule. 

 



Rheumatology leaders are encouraged by

Read Article

Canakinumab Use in Periodic Febrile Disorders

Sep 16, 2021

A retrospective records review of patients with periodic fever syndromes (PFS)  receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.

Read Article

Different Regimens but Equal Outcomes in Polyarticular JIA

Sep 15, 2021

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.



This prospective observational study used data from the STOP-JIA trial (Start Time Optimization of

Read Article

High Drug Switching and Low Persistence in Rheumatoid Arthritis

Sep 13, 2021

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.



This retrospective analysis assessed treatment patterns among patients newly initiated on biologic

Read Article

ACR Comments on JAK Inhibitors and FDA Announcement

ACR
Sep 13, 2021

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article

FDA Review of Vaping Products Extended

Sep 09, 2021

The FDA has again extended its decision on whether the manufacturers of vaping products can market their e-cigarettes in the United States.



Previously, the manufacturers (Juul, Vuse and Blu) were given until September 2020 to submit data to the FDA on the use and safety of these

Read Article

Lymphoma in RA: Disease Activity Matters

MedPage Today
Sep 08, 2021

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for

Read Article

COVID Breakthrough Infections in Rheumatic Patients

Sep 08, 2021

Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.



Researchers

Read Article

Diagnostic Delay in Half of Psoriatic Arthritis Patients

Sep 07, 2021

 A Mayo Clinic/ Olmsted County study of psoriatic arthritis (PsA) patients has shown that more than half (55%) of PsA patients had a diagnostic delay of > 2 years, and that this delay has not improved over time.



A retrospective, population-based cohort examined incident adult PsA

Read Article

Not All Immunosuppression Alters Vaccine Immunogenicity

Sep 02, 2021

Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT)

Read Article

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Sep 02, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

Read Article
The FDA announced its findings regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co. https://t.co/jayl8ufPHn https://t.co/zNvPiVcdOM
Dr. John Cush @RheumNow( View Tweet )
Sep 02, 2021

FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors

Sep 01, 2021

Today, Sept.1st, the FDA announced its decision regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.

These safety concerns arise from

Read Article

Predictors of Inflammatory Arthritis

Aug 31, 2021

Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was

Read Article

Drug Choices After First TNF Inhibitor in RA

Aug 30, 2021

TNFi are frequently used first line in RA patients; and a new analysis shows that repeat use of TNFi dominates over the use of non-TNFi biologics when the initial TNFi therapy has failed. This retrospective analysis of commercial insurance records analyzed the patterns of drug use in adult RA

Read Article

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Aug 26, 2021

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article
×